Research programme: nanomedicine diagnostics and therapeutics - Akrivis Technologies/CEA-Leti
Latest Information Update: 26 Jun 2014
At a glance
- Originator Akrivis Technologies; CEA-LETI
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 19 Jun 2014 Early research in Undefined indication (diagnosis) in France (unspecified route)